Why the study?
Bioprosthetic heart valves face longevity challenges from thrombosis, structural degeneration, calcification, poor re-endothelialization, and inflammation, creating a need for strategies to improve their biocompatibility and longevity.
This review highlights ongoing challenges with bioprosthetic heart valves, such as structural degeneration and calcification, and summarizes strategies to improve their longevity and biocompatibility.
Bioprosthetic valve durability remains a clinical concern; this review leaves open the need for prospective trials of emerging anti-degeneration strategies.
Valvular heart disease (VHD) has become a burden and a growing public health problem in humans, causing significant morbidity and mortality worldwide. An increasing number of patients with severe VHD need to undergo heart valve replacement surgery, and artificial heart valves are in high demand. However, allogeneic valves from donors are lacking and cannot meet clinical practice needs. A mechanical heart valve can activate the coagulation pathway after contact with blood after implantation in the cardiovascular system, leading to thrombosis. Therefore, bioprosthetic heart valves (BHVs) are still a promising way to solve this problem. However, there are still challenges in the use of BHVs. For example, their longevity is still unsatisfactory due to the defects, such as thrombosis, structural valve degeneration, calcification, insufficient re-endothelialization, and the inflammatory response. Therefore, strategies and methods are needed to effectively improve the biocompatibility and longevity of BHVs. This review describes the recent research advances in BHVs and strategies to improve their biocompatibility and longevity.
No takes yet. Share an insight, caveat, or question.
Tong et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: